Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity.
| Autor: | Collie GW; AstraZeneca, Cambridge CB2 0AA, U.K., Clark MA; X-Chem, Inc., Waltham, Massachusetts 02453, United States., Keefe AD; X-Chem, Inc., Waltham, Massachusetts 02453, United States., Madin A; AstraZeneca, Cambridge CB2 0AA, U.K., Read JA; AstraZeneca, Cambridge CB2 0AA, U.K., Rivers EL; AstraZeneca, Cambridge CB2 0AA, U.K., Zhang Y; X-Chem, Inc., Waltham, Massachusetts 02453, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of medicinal chemistry [J Med Chem] 2024 Jan 25; Vol. 67 (2), pp. 864-884. Date of Electronic Publication: 2024 Jan 10. |
| DOI: | 10.1021/acs.jmedchem.3c01861 |
| Abstrakt: | The DNA-encoded library (DEL) discovery platform has emerged as a powerful technology for hit identification in recent years. It has become one of the major parallel workstreams for small molecule drug discovery along with other strategies such as HTS and data mining. For many researchers working in the DEL field, it has become increasingly evident that many hits and leads discovered via DEL screening bind to target proteins with unique and unprecedented binding modes. This Perspective is our attempt to analyze reports of DEL screening with the purpose of providing a rigorous and useful account of the binding modes observed for DEL-derived ligands with a focus on binding mode novelty. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|